Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva    VLA   FR0004056851

VALNEVA (VLA)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA
06/08 VALNEVA : Announces the Availability of Documentation for its Meetings of Shareh..
06/07 VALNEVA : to Present at Jefferies 2017 Global Healthcare Conference in New York
06/06 VALNEVA : to Present at Jefferies 2017 Global Healthcare Conference in New York
05/11 VALNEVA : Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financi..
05/11 VALNEVA : Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financ..
05/08VALNEVA SE : quaterly earnings release
04/19 VALNEVA : Announces Signing of a New EB66 Commercial License with Bavarian Nordi..
04/19 VALNEVA : Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech
04/18 VALNEVA : Announces Signing of a New EB66® Commercial License with Bavarian Nord..
04/18 VALNEVA : Announces Signing of a New EB66® Commercial License with Bavarian Nord..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/09 Valneva SE (INRLF) Presents At Jefferies 2017 Global Healthcare Conference - ..
Advertisement
Financials (€)
Sales 2017 111 M
EBIT 2017 -3,20 M
Net income 2017 -7,80 M
Debt 2017 3,30 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 45,85
EV / Sales 2017 2,12x
EV / Sales 2018 1,74x
Capitalization 231 M
More Financials
Chart VALNEVA
Duration : Period :
Valneva Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 4,51 €
Spread / Average Target 51%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Thomas Lingelbach President & Chief Executive Officer
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
James R. Sulat Vice Chairman-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA-3.56%260
INCYTE CORPORATION34.31%27 907
QUINTILES IMS HOLDINGS..18.58%19 657
LONZA GROUP27.74%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC5.20%8 957
More Results